NASDAQ:SLRX Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free SLRX Stock Alerts $0.53 +0.05 (+9.28%) (As of 02:32 PM ET) Add Compare Share Share Today's Range$0.49▼$0.5550-Day Range$0.49▼$0.6852-Week Range$0.43▼$2.68Volume57,323 shsAverage Volume114,313 shsMarket Capitalization$2.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Salarius Pharmaceuticals alerts: Email Address Salarius Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.63) to ($4.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.11 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Salarius Pharmaceuticals. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.36% of the float of Salarius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSalarius Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Salarius Pharmaceuticals has recently decreased by 20.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSalarius Pharmaceuticals does not currently pay a dividend.Dividend GrowthSalarius Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLRX. Previous Next 3.2 News and Social Media Coverage News SentimentSalarius Pharmaceuticals has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Salarius Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest1 people have searched for SLRX on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Salarius Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Salarius Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 11.88% of the stock of Salarius Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Salarius Pharmaceuticals are expected to grow in the coming year, from ($4.63) to ($4.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Salarius Pharmaceuticals is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Salarius Pharmaceuticals is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSalarius Pharmaceuticals has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Salarius Pharmaceuticals Stock (NASDAQ:SLRX)Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.Read More SLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLRX Stock News HeadlinesMarch 27, 2024 | msn.comWall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation DataMarch 25, 2024 | msn.comWhy Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving PremarketMarch 28, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 23, 2024 | finanznachrichten.deSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 22, 2024 | sfgate.comSalarius: Q4 Earnings SnapshotMarch 22, 2024 | globenewswire.comSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 5, 2024 | msn.comQuoin stock craters 47% on public offering after rallying in prior sessionMarch 4, 2024 | msn.comQuoin stock soars 60% on FDA update for ichthyosis drugMarch 28, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:February 22, 2024 | markets.businessinsider.comSalarius Pharmaceuticals Implements Cost-savings MeasuresFebruary 22, 2024 | msn.comSalarius's CEO David Arthur steps downFebruary 22, 2024 | finance.yahoo.comSalarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing ExpensesFebruary 9, 2024 | uk.investing.comSalarius Pharmaceuticals Inc (SLRX)January 16, 2024 | finance.yahoo.comSalarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein DegradersJanuary 13, 2024 | wsj.comSquare Pharmaceuticals Ltd.January 3, 2024 | finance.yahoo.comInvestigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient EnrollmentNovember 10, 2023 | finance.yahoo.comSLRX Continues Work as it Seeks AlternativesNovember 8, 2023 | morningstar.comSalarius Pharmaceuticals Inc SLRXNovember 7, 2023 | finance.yahoo.comSalarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development ProgramAugust 10, 2023 | bizjournals.comSalarius Pharmaceuticals cuts half of workforce despite positive clinical developmentsAugust 10, 2023 | finance.yahoo.comSalarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business UpdateAugust 9, 2023 | finance.yahoo.comSLRX Pursuing Strategic AlternativesJuly 11, 2023 | benzinga.comWatching Salarius Pharma; Zacks Small-Cap Research Sets $6.75 Price TargetJuly 11, 2023 | finance.yahoo.comSLRX Continues Cancer Fight with Phase I Trial ApprovalJuly 11, 2023 | marketwatch.comSalarius Pharmaceuticals Gets FDA Clearance for Lymphoma Drug ApplicationJuly 11, 2023 | finance.yahoo.comSalarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma PatientsJune 12, 2023 | finance.yahoo.comSalarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid CongressSee More Headlines Receive SLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2023Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SLRX CUSIPN/A CIK1615219 Webwww.salariuspharma.com Phone(832) 834-6992FaxN/AEmployees12Year Founded2011Profitability EPS (Most Recent Fiscal Year)($4.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-197.96% Return on Assets-135.23% Debt Debt-to-Equity RatioN/A Current Ratio5.02 Quick Ratio3.59 Sales & Book Value Annual Sales$1.84 million Price / Sales1.20 Cash FlowN/A Price / Cash FlowN/A Book Value$4.56 per share Price / Book0.11Miscellaneous Outstanding Shares4,310,000Free Float3,721,000Market Cap$2.20 million OptionableNot Optionable Beta1.04 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. David J. Arthur M.B.A. (Age 61)CEO, President & Director Comp: $729.58kMr. Mark J. Rosenblum CPA (Age 71)Executive VP of Finance & CFO Comp: $409.98kDr. Nadeem Q. Mirza M.D.M.P.H., Senior Vice President of Clinical DevelopmentDr. Daniela Y. SantiestebanDirector of Targeted Protein Degradation ProgramKey CompetitorsClearmind MedicineNASDAQ:CMNDAllarity TherapeuticsNASDAQ:ALLRNeuBase TherapeuticsNASDAQ:NBSEPhio PharmaceuticalsNASDAQ:PHIOInMed PharmaceuticalsNASDAQ:INMView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 137,000 shares on 2/13/2024Ownership: 2.234%View All Institutional Transactions SLRX Stock Analysis - Frequently Asked Questions Should I buy or sell Salarius Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Salarius Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SLRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLRX, but not buy additional shares or sell existing shares. View SLRX analyst ratings or view top-rated stocks. How have SLRX shares performed in 2024? Salarius Pharmaceuticals' stock was trading at $0.65 at the beginning of the year. Since then, SLRX stock has decreased by 17.6% and is now trading at $0.5353. View the best growth stocks for 2024 here. Are investors shorting Salarius Pharmaceuticals? Salarius Pharmaceuticals saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 14,400 shares, a decrease of 20.0% from the February 29th total of 18,000 shares. Based on an average daily trading volume, of 104,500 shares, the short-interest ratio is presently 0.1 days. Approximately 0.4% of the company's shares are short sold. View Salarius Pharmaceuticals' Short Interest. When is Salarius Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SLRX earnings forecast. How were Salarius Pharmaceuticals' earnings last quarter? Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announced its earnings results on Monday, March, 27th. The company reported ($2.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.16) by $0.67. What ETFs hold Salarius Pharmaceuticals' stock? ETFs with the largest weight of Salarius Pharmaceuticals (NASDAQ:SLRX) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX), When did Salarius Pharmaceuticals' stock split? Salarius Pharmaceuticals shares reverse split on Monday, October 17th 2022. The 1-25 reverse split was announced on Monday, October 17th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Salarius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Salarius Pharmaceuticals investors own include Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA), Biocept (BIOC), DURECT (DRRX), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX). Who are Salarius Pharmaceuticals' major shareholders? Salarius Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (2.23%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Arnold C Hanish, David J Arthur, Mark J Rosenblum and William K Mcvicar. View institutional ownership trends. How do I buy shares of Salarius Pharmaceuticals? Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLRX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeAI to Meet the Same Fate as EVs? Porter & CompanyGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.